Pyxis Oncology (PYXS) Non Operating Income (2020 - 2026)
Pyxis Oncology (PYXS) posted quarterly Non Operating Income of $1.3 million for Q4 2025, down 44.64% year-over-year from $2.3 million in Q4 2024, and down 11.39% quarter-over-quarter from $1.5 million in Q3 2025.
Pyxis Oncology (PYXS) Non Operating Income (2020 - 2026) Analysis & Trends
Pyxis Oncology (PYXS) has reported Non Operating Income for 6 consecutive years, with $1.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non Operating Income fell 44.64% year-over-year to $1.3 million; the TTM figure through Dec 2025 stood at $6.2 million (down 37.93% YoY), while the FY2025 annual figure was $6.2 million, down 37.93% from the prior year.
- Non Operating Income retreated to $1.3 million in Q4 2025 per PYXS's latest filing, from $1.5 million in the prior quarter.
- Across five years, Non Operating Income topped out at $2.7 million in Q2 2024 and bottomed at -$2.6 million in Q3 2021.
- Historically, Non Operating Income has averaged $1.1 million across 5 years, with a median of $1.7 million in 2023.
- Annual changes were most pronounced in 2021 — Non Operating Income tumbled 255500.0% — and 2023, when it jumped 18911.11%.
- Pyxis Oncology's Non Operating Income stood at -$403000.0 in 2021, then surged by 564.52% to $1.9 million in 2022, then grew by 15.92% to $2.2 million in 2023, then gained by 7.56% to $2.3 million in 2024, then plunged by 44.64% to $1.3 million in 2025.
- Business Quant data shows PYXS's Non Operating Income at $1.3 million in Q4 2025, $1.5 million in Q3 2025, and $1.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Pyxis Oncology | 198.37 Mn | 165.38 Mn | - | 644,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 644,000.00 |
| Dec 31, 2025 | 1.29 Mn |
| Sep 30, 2025 | 1.46 Mn |
| Jun 30, 2025 | 1.68 Mn |
| Mar 31, 2025 | 1.76 Mn |
| Dec 31, 2024 | 2.33 Mn |
| Sep 30, 2024 | 2.55 Mn |
| Jun 30, 2024 | 2.73 Mn |
| Mar 31, 2024 | 2.35 Mn |
| Dec 31, 2023 | 2.17 Mn |
| Sep 30, 2023 | 2.31 Mn |
| Jun 30, 2023 | 2.22 Mn |
| Mar 31, 2023 | 1.71 Mn |
| Dec 31, 2022 | 1.87 Mn |
| Sep 30, 2022 | 719,000.00 |
| Jun 30, 2022 | 164,000.00 |
| Mar 31, 2022 | 9,000.00 |
| Dec 31, 2021 | -403,000.00 |
| Sep 30, 2021 | -2.55 Mn |
| Jun 30, 2021 | -1.97 Mn |